Clinical Trials · NCT02128932
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,089
- Start date
- Aug 2014
- Locations
- 231 sites, 15 countries
- Primary endpoint
- Change in HbA1c From Baseline